Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025 at 3:20 pm ET.
https://mma.prnewswire.com/media/2646316/Edgewise_Therapeutics_Logo.jpg
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations pageand will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to:www.edgewisetx.comor follow us onLinkedIn,X,FacebookandInstagram.
https://c212.net/c/img/favicon.png?sn=LA01020&sd=2025-06-03
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-annual-goldman-sachs-global-healthcare-conference-302470973.html
SOURCE Edgewise Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=LA01020&Transmission_Id=202506030800PR_NEWS_USPR_____LA01020&DateId=20250603